Table 2.

Association of clinical characteristics at enrollment with incidence of AIDS defining opportunistic infections and cancers

	Any OI Incidence (n=135)		Any Cancer Incidence (n=45)
	RRb	Pb	RRb	Pb
Enrollment cohort
1998–2002	Ref		Ref
2003–2005	0.83	0.48	0.84	0.69
2006–2012	0.37	0.01	0.58	0.31
AIDS diagnosis category
CD4+ T-cell lymphopenia	Ref		Ref
Opportunistic infection or malignancy	0.85	0.48	1.36	0.37
Race
White	Ref		Ref
Black	1.65	0.008	0.66	0.22
Other	0.68	0.22	0.84	0.69
Sex
Male	Ref		Ref
Female	1.22	0.37	0.99	0.97
Enrollment median age
≥43	Ref		Ref
<43	1.35	0.09	0.98	0.94
HIV transmission category Male to male sexual contact	Ref		Ref
Injection drug usec	0.86	0.62	0.57	0.29
Other	1.06	0.79	0.58	0.13
Enrollment CD4+T-Cells (cells/uL)
≥500	Ref		Ref
200–500	1.12	0.78	1.56	0.56
<200	3.31	0.001	3.59	0.08
Nadir CD4+T-Cells (cells/uL)
≥50	Ref		Ref
<50	1.71	0.003	0.89	0.72
Enrollment HIV load (log10[copies/ml])
< 2.6	Ref		Ref
2.6–5	1.78	0.04	3.06	0.02
≥ 5	4.74	<.0001	4.15	0.002
Maximum prior HIV load (log10[copies/ml])
<5	Ref		Ref
≥ 5	2.27	0.01	2.04	0.24
Enrollment ARTd
No ART	Ref		Ref
ART (no cART)	0.70	0.32	0.57	0.34
cART	0.37	<.0001	0.31	0.002

^a.Likelihood ratio Chi square P values.

^b.Relative Risk. Cox models with staggered entries based on time since diagnosis of AIDS

^c.Injection drug use category includes persons with any injection drug use.

^d.No ART is no anti-retroviral usage reported at study entry; ART is any anti-retroviral treatment that is not considered cART; cART regimen is at least 2 different ART in combination that qualifies modern cART classifications (see Methods for details).